![Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial | Semantic Scholar Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cbf40210606e2a1de2e6ed64d6621eb468e1db48/5-Table3-1.png)
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial | Semantic Scholar
![A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac | Pain and Therapy A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac | Pain and Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40122-018-0100-2/MediaObjects/40122_2018_100_Fig3_HTML.png)
A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac | Pain and Therapy
![Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2002/nejm_2002.347.issue-26/nejmoa021907/production/images/img_medium/nejmoa021907_t4.jpeg)
Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM
![Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis | Arthritis Research & Therapy | Full ... Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis | Arthritis Research & Therapy | Full ...](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-015-0554-0/MediaObjects/13075_2015_554_Fig1_HTML.gif)
Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis | Arthritis Research & Therapy | Full ...
![Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/63c765d9-c539-4d2f-8fde-eb1a58bf13e8/joim13505-gra-0001-m.jpg)
Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library
![Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2002/nejm_2002.347.issue-26/nejmoa021907/production/images/img_small/nejmoa021907_f1.jpeg)
Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM
![Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study - ScienceDirect Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002934305009137-gr1.jpg)
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study - ScienceDirect
![Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction | Journal of the American College of Cardiology Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/0174af37-6db2-4b29-924c-843fcdc2712f/fx1.jpg)
Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction | Journal of the American College of Cardiology
![Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016 Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016](https://journals.sagepub.com/cms/10.1177/0300060516628704/asset/images/large/10.1177_0300060516628704-fig2.jpeg)
Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016
![PDF) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients PDF) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients](https://i1.rgstatic.net/publication/298424480_Celecoxib_versus_diclofenac_for_the_treatment_of_ankylosing_spondylitis_12-week_randomized_study_in_Norwegian_patients/links/56ee9d9308ae4b8b5e75086d/largepreview.png)
PDF) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients
![Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016 Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016](https://journals.sagepub.com/cms/10.1177/0300060516628704/asset/images/large/10.1177_0300060516628704-fig1.jpeg)
Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016
![Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: A randomized double-blind, non-inferiority trial - Ana C Gordo, Chris Walker, Beatriz Armada, Duo Zhou, 2017 Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: A randomized double-blind, non-inferiority trial - Ana C Gordo, Chris Walker, Beatriz Armada, Duo Zhou, 2017](https://journals.sagepub.com/cms/10.1177/0300060516673707/asset/images/large/10.1177_0300060516673707-fig1.jpeg)
Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: A randomized double-blind, non-inferiority trial - Ana C Gordo, Chris Walker, Beatriz Armada, Duo Zhou, 2017
![Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/21bff47b-52e2-4d1f-b271-23ecf9014267/joim13505-fig-0003-m.jpg)